Artiva Biotherapeutics (ARTV) priced its underwritten offering of about 23.9 million common shares at $11.52 per share and, in lieu of common shares for certain investors, pre-funded warrants to purchase about 2.2 million common shares at $11.52 per share, for a total of approximately $300 million.
The company expects to close the offering on or about May 11, according to a Friday statement from Artiva.
Shares of Artiva Biotherapeutics were up more than 17% premarket Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.